Aerie Pharma (AERI) Misses Q3 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aerie Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
November 6, 2018 4:01 PM ESTConference Call and Webcast Today, November 6th, at 5:00 p.m. ET
DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, today reported financial results for the third quarter ended September30, 2018, along with a general business update.
Aerie Highlights
Rhopressa® (netarsudil ophthalmic solution) 0.02% generated third quarter net revenues on a U.S. GAAP (generally accepted accounting... More